Skip to content
Sachs Forum 2025 Slide Presentation
View Presentation
Strategic Partnering
News
Presentations
Contact Us
Strategic Partnering
News
Presentations
Contact Us
Invest now
Disease Areas
Topical Scarring & Burns
Organ Fibrosis
Autoimmune Disorders
Wrinkles & Rhytids
Our Science
Kynurenic Acid MoA
Immune Cells Therapy
University of British Columbia
Products & Pipeline
Clinical Program NHP/OTC and Cosmetics
Rx Clinical Program
About Us
Our Mission
Leadership
Grants
Disease Areas
Topical Scarring & Burns
Organ Fibrosis
Autoimmune Disorders
Wrinkles & Rhytids
Our Science
Kynurenic Acid MoA
Immune Cells Therapy
University of British Columbia
Products & Pipeline
Clinical Program NHP/OTC and Cosmetics
Rx Clinical Program
About Us
Our Mission
Leadership
Grants
Disease Areas
Topical Scarring & Burns
Organ Fibrosis
Autoimmune Disorders
Wrinkles & Rhytids
Our Science
Kynurenic Acid MoA
Immune Cells Therapy
University of British Columbia
Products & Pipeline
Clinical Program NHP/OTC and Cosmetics
Rx Clinical Program
About Us
Our Mission
Leadership
Grants
Strategic Partnering
News
Presentations
Contact Us
Disease Areas
Topical Scarring & Burns
Organ Fibrosis
Autoimmune Disorders
Wrinkles & Rhytids
Our Science
Kynurenic Acid MoA
Immune Cells Therapy
University of British Columbia
Products & Pipeline
Clinical Program NHP/OTC and Cosmetics
Rx Clinical Program
About Us
Our Mission
Leadership
Grants
Strategic Partnering
News
Presentations
Contact Us
Positive Topline Data from Phase 2 Study of FS2 for Treatment of Keloid Scars
01-21-2021-BirchBioMed-FS2-trial-results_FINAL
